Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
John N. Allan, MD, discusses current data detailing the activity of venetoclax-based, fixed-duration regimens in the frontline setting for patients with chronic lymphocytic leukemia; the synergy and promising efficacy signals seen with BCL-2 and BTK inhibitor combinations; and ongoing research efforts exploring triplet regimens vs other continuous approaches in this space.
Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.
The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.
Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.
Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia.